Global Cannabis Applications Corp. (“GCAC” or the “Company”) (CSE: APP, FSE:2FA, OTCQB: FUAPF), a leading developer of innovative data technologies for the cannabis industry, is pleased to announce that it has established an office in Europe with its head office in Lithuania. GCAC Lithuania will be the first medical cannabis company in the country. GCAC Europe will be established with assistance from Mr. Antanas Guoga, a shareholder who was appointed to the GCAC advisory board on November 21, 2017. Gouga will take an active role with GCAC in Europe as it launches its innovative technology for the medical cannabis industry.
“I am very honoured to be part of the emerging blockchain based initiative which serves for the scientific research for the medical cannabis industry which is one of the most underestimated medical areas in Europe. Transparency and efficiency are the essentials of the blockchain technology used by GCAC that are also crucial to me. Moreover, I am happy that the global innovative company is going to use the talents pool in my home country of Lithuania where the industry for the blockchain technology is developing extremely fast,” said Antanas Guoga, Member of the European Parliament. “As a strategic advisor to GCAC, I recognize that the Citizen Green medical cannabis data platform will be important in assisting medical cannabis stakeholders by capturing, aggregating and delivering data in a trusted blockchain environment. This is an important milestone for both GCAC and the newly emerging European medical innovation markets.”
On November 14, members of the Lithuanian parliament voted to consider an amendment to the country’s drug policy. Parliament recognizes the benefits of cannabis medicines for severely ill patients, and the voted almost unanimously to consider a legislative amendment that could legalize medical cannabis and other currently prohibited drugs, and potentially open the door for the medicinal use of cannabis in Lithuania.
“Europe, and Lithuania particularly is an emerging medical innovations market which can benefit from our end-to-end data aggregation and user delivery system for the medical cannabis industry,” said Brad Moore, CEO of GCAC. “Tony G is well known and regarded in the country as an opinion leader for the innovative solutions, and will be invaluable resource as we navigate the political landscape and introduce blockchain and cryptocurrencies to the medical cannabis landscape in Lithuania.”
About Global Cannabis Applications Corp.
Global Cannabis Applications Corp. is a global leader in designing, developing, marketing, and acquiring innovative data technologies for the cannabis industry. The Citizen Green platform is the world’s first end-to-end – from patient to regulator – medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, reg tech, smart databases, blockchain and digital reward tokens, to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in medical cannabis. Managed by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.
For more information about the Company, please visit online at www.cannappscorp.com, or review its profiles www.sedar.com and on the Canadian Securities Exchange’s website (www.thecse.com).
To schedule an interview, please contact:
Chief Executive Officer
For more information, please contact:
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.
Click here to connect with Global Cannabis Applications Corp. (CSE: APP, FSE:2FA, OTCQB: FUAPF) for an Investor Presentation
Pineapple Express Delivery Partners with CannTrust to Offer Same-Day and Next-Day Delivery for estoraTM Medical Cannabis Patients in Ontario
Ensuring estoraTMpatients have seamless access to their high-quality medical cannabis products
World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announce that its subsidiary Pineapple Express Delivery Inc. (“Pineapple Express Delivery” or “PED”), a leading logistics technology company offering compliant and secure delivery of controlled substances and regulated products, has partnered with CannTrust Inc. to bring same-day and next-day delivery to estoraTM medical cannabis patients in Ontario
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.